Jonathan S. Berek

Publication Details

  • Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? HAMILTON, T. C., Berek, J. S., Kaye, S. B. OXFORD UNIV PRESS. 1999: 69-73

    Abstract:

    The scientific community, which studies ovarian cancer in the laboratory, is making progress in understanding many aspects of the disease. At present there is evidence that the cancer prone ovary has a preneoplastic phenotype. These genetic changes may constitute a surrogate intermediate end-point biomarker of cancer risk, which might be altered by preventive measures. Studies that aim at understanding the genetic basis of the disease are reviewed. Many of these studies use clinical ovarian cancer samples. To augment study of clinical specimens, an experimental system has been developed where malignancy is induced in the rat ovarian surface epithelium (ROSE). This system markedly facilitates examination of how genes fit into the ovarian cancer puzzle. The problem of drug resistance in ovarian cancer has received considerable attention. Although the functional changes responsible for resistance have been identified there has been little progress in identifying the actual genes capable of conferring the substantial resistance seen in cell lines.

    View details for Web of Science ID 000080354700013

    View details for PubMedID 10219457

Stanford Medicine Resources:

Footer Links: